8-K filings / November 18, 2026
Phathom Pharmaceuticals, Inc.: A change of officers or directors
Phathom Pharmaceuticals, Inc. filed a current report (Form 8-K) with the SEC on November 18, 2026. It reports a change of officers or directors.
AI-written from the facts below
In plain English
Robert Breedlove will leave the role of Vice President, Finance, effective December 4, 2026. This change is reported under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed.
What each sentence states
“Robert Breedlove will leave the role of Vice President, Finance, effective December 4, 2026.”
- Item 5.02: Robert Breedlove leaves the role of Vice President, Finance, effective December 4, 2026.
“This change is reported under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed.”
- Item 5.02 of Form 8-K covers directors and senior officers who leave or are appointed.
- Item 5.02: Robert Breedlove leaves the role of Vice President, Finance, effective December 4, 2026.
Item 5.02
Officers and directors
-
Leaves
Robert Breedlove, Vice President, FinanceEffective December 4, 2026
From the filing
Source
“On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals, Inc. (the “Company”) notified the Company of his decision to resign from the Company, effective December 4, 2026.”
Found by an AI model; the quote is checked word for word against the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.